Expression of apelin‑13 and its negative correlation with TGF‑β1 in patients with diabetic kidney disease

Wang,Qi; Liu,Xujing; Zhai,Aihua; Xu,Hua; Ma,Shizhan; Liu,Yulin

doi:10.3892/etm.2024.12398

Expression of apelin‑13 and its negative correlation with TGF‑β1 in patients with diabetic kidney disease

Authors:
- Qi Wang
- Xujing Liu
- Aihua Zhai
- Hua Xu
- Shizhan Ma
- Yulin Liu
View Affiliations

Affiliations: Department of Pharmacy, The Fifth People's Hospital of Jinan, Jinan, Shandong 250022, P.R. China, Department of Clinical Laboratory, The Fifth People's Hospital of Jinan, Jinan, Shandong 250022, P.R. China, Department of Endocrinology, The Fifth People's Hospital of Jinan, Jinan, Shandong 250022, P.R. China, Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250022, P.R. China, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong 250013, P.R. China
Published online on: January 23, 2024 https://doi.org/10.3892/etm.2024.12398
Article Number: 110

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic kidney disease (DKD) is a severe microvascular complication of diabetes, one key feature of which includes renal fibrosis. As apelin is an adipokine closely related to diabetes, the present study aimed to evaluate apelin‑13 expression levels and the relationship between apelin‑13 and disease indicators in patients with diabetic kidney disease (DKD). The present case‑control study enrolled 70 patients with diabetes, including 31 with diabetic kidney disease (DKD group), 39 without DKD (non‑DKD group) and 30 healthy controls. The levels of serum apelin‑13 and TGF‑β1, the key driver of renal fibrosis, were determined by ELISA. Additionally, age, mean disease duration, weight, blood pressure, fasting blood glucose, triglyceride, low‑density lipoprotein cholesterol, high‑density lipoprotein, cholesterol, urea nitrogen, blood creatinine and 24‑hour urinary total protein (24‑h UTP) were recorded. The results demonstrated that apelin‑13 and TGF‑β1 expression levels, age, blood pressure, fasting blood glucose, cholesterol and blood urea nitrogen levels were significantly higher in patients with diabetes compared with the healthy controls (P<0.05). Moreover, apelin‑13 and TGF‑β1 expression levels, mean disease duration, systolic pressure, blood creatinine, blood urea nitrogen and 24‑h UTP were significantly higher in the DKD group compared with the non‑DKD group (P<0.05). The estimated glomerular filtration rate (eGFR) was significantly reduced in the DKD group compared with the non‑DKD group (P<0.05). Correlation analysis demonstrated a negative correlation between apelin‑13 and eGFR expression and a positive correlation between apelin‑13 expression and 24‑h UTP in both the DKD and non‑DKD groups (P<0.05). A negative correlation was also demonstrated between apelin‑13 and TGF‑β1 expression levels in the DKD group and non‑DKD groups (both P<0.05). In conclusion, apelin‑13 and TGF‑β1 expression levels were significantly higher in the DKD group compared with those in the non‑DKD group. Additionally, apelin‑13 expression was negatively correlated with TGF‑β1 expression in the DKD and non‑DKD groups. Therefore, apelin‑13 could potentially be used in the future as an indicator of renal fibrosis or destruction in patients with DKD. The present trial was retrospectively registered in the Chinese Clinical Trial Registry (trial registration no. ChiCTR2200060945) on 14.06.2022.

View Figures

View References

1	Ahmad J: Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab Syndr. 9:343–58. 2015.PubMed/NCBI View Article : Google Scholar
2	Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B, et al: Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: National cross sectional study. BMJ. 369(m997)2020.PubMed/NCBI View Article : Google Scholar
3	Weng JP and Bi Y: Epidemiological status of chronic diabetic complications in China. Chin Med J (Engl). 128:3267–3269. 2015.PubMed/NCBI View Article : Google Scholar
4	Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G and Ekinci EI: Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 8:6–18. 2017.PubMed/NCBI View Article : Google Scholar
5	Zhang Y, Jin D, Kang X, Zhou R, Sun Y, Lian F and Tong X: Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev Biol. 9(696542)2021.PubMed/NCBI View Article : Google Scholar
6	Carew RM, Wang B and Kantharidis P: The role of EMT in renal fibrosis. Cell Tissue Res. 347:103–116. 2012.PubMed/NCBI View Article : Google Scholar
7	Sisto M, Lorusso L, Ingravallo G, Tamma R, Ribatti D and Lisi S: The TGF-β1 signaling pathway as an attractive target in the fibrosis pathogenesis of Sjögren's syndrome. Mediators Inflamm. 2018(1965935)2018.PubMed/NCBI View Article : Google Scholar
8	Sawires H, Botrous O, Aboulmagd A, Madani N and Abdelhaleem O: Transforming growth factor-β1 in children with diabetic nephropathy. Pediatr Nephrol. 34:81–85. 2019.PubMed/NCBI View Article : Google Scholar
9	Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX and Zhao HL: Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy. A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 96(e6583)2017.PubMed/NCBI View Article : Google Scholar
10	Zheng ZC, Zhu W, Lei L, Liu XQ and Wu YG: Wogonin ameliorates renal inflammation and fibrosis by inhibiting NF-κB and TGF-β1/Smad3 signaling pathways in diabetic nephropathy. Drug Des Devel Ther. 14:4135–4148. 2020.PubMed/NCBI View Article : Google Scholar
11	Sun Z, Ma Y, Chen F, Wang S, Chen B and Shi J: miR-133b and miR-199b knockdown attenuate TGF-β1-induced epithelial to mesenchymal transition and renal fibrosis by targeting SIRT1 in diabetic nephropathy. Eur J Pharmacol. 837:96–104. 2018.PubMed/NCBI View Article : Google Scholar
12	Geng XQ, Ma A, He JZ, Wang L, Jia YL, Shao GY, Li M, Zhou H, Lin SQ and Ran JH: Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways. Acta Pharmacol Sin. 41:670–677. 2020.PubMed/NCBI View Article : Google Scholar
13	Miao XJ, Bi TT, Tang JM, Lv R, Gui DK and Yang XF: Regulatory mechanism of TGF-β1/SGK1 pathway in tubulointerstitial fibrosis of diabetic nephropathy. Eur Rev Med Pharmacol Sci. 23:10482–10488. 2019.PubMed/NCBI View Article : Google Scholar
14	Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, et al: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 251:471–476. 1998.PubMed/NCBI View Article : Google Scholar
15	Chapman FA, Nyimanu D, Maguire JJ, Davenport AP, Newby DE and Dhaun N: The therapeutic potential of apelin in kidney disease. Nat Rev Nephrol. 17:840–853. 2021.PubMed/NCBI View Article : Google Scholar
16	Habchi M, Duvillard L, Cottet V, Brindisi MC, Bouillet B, Beacco M, Crevisy E, Buffier P, Baillot-Rudoni S, Verges B and Petit JM: Circulating apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control. Clin Endocrinol (Oxf). 81:696–701. 2014.PubMed/NCBI View Article : Google Scholar
17	Demirpence M, Yilmaz H, Colak A, Pamuk BO, Karakoyun I and Basok B: Apelin: A potential novel serum biomarker for early detection of diabetic nephropathy in patients with type 2 diabetes. North Clin Istanb. 6:151–155. 2118.PubMed/NCBI View Article : Google Scholar
18	Iwano M: EMT and TGF-beta in renal fibrosis. Front Biosci (Schol Ed). 2:229–238. 2010.PubMed/NCBI View Article : Google Scholar
19	Lv SY, Yang YJ and Chen Q: Regulation of feeding behavior, gastrointestinal function and fluid homeostasis by apelin. Peptides. 44:87–92. 2013.PubMed/NCBI View Article : Google Scholar
20	Zhang Y, Jiang W, Sun W, Guo W, Xia B, Shen X, et al: Neuroprotective Roles of Apelin-13 in Neurological Diseases. Neurochem Res. 48:1648–1662. 2023.PubMed/NCBI View Article : Google Scholar
21	Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP and STROBE Initiative: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet. 370:1453–1457. 2007.PubMed/NCBI View Article : Google Scholar
22	Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98(4S):S1–S115. 2020.PubMed/NCBI View Article : Google Scholar
23	Brownlee M: The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 54:1615–1625. 2005.PubMed/NCBI View Article : Google Scholar
24	Stevens PE and Levin A: Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 158:825–830. 2013.PubMed/NCBI View Article : Google Scholar
25	Zhang BH, Wang W, Wang H, Yin J and Zeng XJ: Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One. 8(e60457)2013.PubMed/NCBI View Article : Google Scholar
26	Day RT, Cavaglieri RC and Feliers D: Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol. 304:F788–F800. 2013.PubMed/NCBI View Article : Google Scholar
27	Meral C, Tascilar E, Karademir F, Tanju IA, Cekmez F, Ipcioglu OM, Ercin CN, Gocmen I and Dogru T: Elevated plasma levels of apelin in children with type 1 diabetes mellitus. J Pediatric Endocrinol Metab. 23:497–502. 2010.PubMed/NCBI View Article : Google Scholar
28	Meng XM, Nikolic-Paterson DJ and Lan HY: TGF-β: The master regulator of fibrosis. Nat Rev Nephrol. 12:325–338. 2016.PubMed/NCBI View Article : Google Scholar
29	Wang LY, Diao ZL, Zhang DL, Zheng JF, Zhang QD, Ding JX and Liu WH: The regulatory peptide apelin: A novel inhibitor of renal interstitial fibrosis. Amino Acids. 46:2693–2704. 2014.PubMed/NCBI View Article : Google Scholar
30	Kocer D, Karakukcu C, Ozturk F, Eroglu E and Kocyigit I: Evaluation of fibrosis markers: Apelin and transforming growth factor-β1 in autosomal dominant polycystic kidney disease patients. Ther Apher Dial. 20:517–522. 2016.PubMed/NCBI View Article : Google Scholar
31	Chen H, Wan D, Wang L, Peng A, Xiao H, Petersen RB, Liu C, Zheng L and Huang K: Apelin protects against acute renal injury by inhibiting TGF-β1. Biochim Biophys Acta. 1852:1278–1287. 2015.PubMed/NCBI View Article : Google Scholar
32	Lu LL, Hu XJ, Yang Y, Xu S, Yang SY, Zhang CY and Zhao QY: Correlation of myopia onset and progression with corneal biomechanical parameters in children. World J Clin Cases. 10:1548–1556. 2022.PubMed/NCBI View Article : Google Scholar
33	Liu Y, Zhang J, Wang YJ and Zeng XJ: Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes. Cell Death Dis. 8(e3006)2017.PubMed/NCBI View Article : Google Scholar
34	Yin J, Wang Y, Chang J, Li B, Zhang J, Liu Y, Lai S, Jiang Y, Li H and Zeng X: Apelin inhibited epithelial-mesenchymal transition of podocytes in diabetic mice through downregulating immunoproteasome subunits β5i. Cell Death Dis. 9(1031)2018.PubMed/NCBI View Article : Google Scholar
35	Gao Z, Zhong X, Tan YX and Liu D: Apelin-13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis. Int J Mol Med. 48(175)2021.PubMed/NCBI View Article : Google Scholar
36	Zaki M, Kamal S, Ezzat W, Hassan N, Yousef W, Ryad H, Mohamed R, Youness E, Basha W and Elhosary Y: Serum apelin levels and metabolic risk markers in obese women. J Genet Eng Biotechnol. 15:423–429. 2017.PubMed/NCBI View Article : Google Scholar
37	Bertrand C, Pradère JP, Geoffre N, Deleruyelle S, Masri B, Personnaz J, Le Gonidec S, Batut A, Louche K, Moro C, et al: Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice by an indirect mechanism. Endocrine. 60:112–121. 2018.PubMed/NCBI View Article : Google Scholar
38	Zheng XD, Huang Y and Li H: Regulatory role of Apelin-13-mediated PI3K/AKT signaling pathway in the glucose and lipid metabolism of mouse with gestational diabetes mellitus. Immunobiology. 226(152135)2021.PubMed/NCBI View Article : Google Scholar